TIM-3 as a potential exhaustion marker in CD4
CD39
COVID-19
PD-1
TIM-3
exhausted Cell
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
15
08
2021
received:
16
02
2021
accepted:
17
08
2021
pubmed:
10
9
2021
medline:
18
11
2021
entrez:
9
9
2021
Statut:
ppublish
Résumé
COVID-19 causes a range of clinical symptoms from mild to critical and can be life-threatening. Up to now, it has led to many deaths. We aimed to evaluate exhausted markers on CD4 In this study, we evaluated 44 patients with confirmed COVID-19 disease and 16 healthy individuals. Patients were divided into moderate/severe and critical groups. Peripheral blood mononuclear cells (PBMCs) were isolated and stained by anti-human CD39, PD-1, TIM-3, and anti-human CD4. The percentage of each CD4 We detected overexpression of TIM-3 on CD4 T cell exhaustion occurs during COVID-19 disease and TIM-3 is the most important exhausted marker on CD4
Sections du résumé
BACKGROUND
COVID-19 causes a range of clinical symptoms from mild to critical and can be life-threatening. Up to now, it has led to many deaths. We aimed to evaluate exhausted markers on CD4
METHODS
In this study, we evaluated 44 patients with confirmed COVID-19 disease and 16 healthy individuals. Patients were divided into moderate/severe and critical groups. Peripheral blood mononuclear cells (PBMCs) were isolated and stained by anti-human CD39, PD-1, TIM-3, and anti-human CD4. The percentage of each CD4
RESULTS
We detected overexpression of TIM-3 on CD4
CONCLUSION
T cell exhaustion occurs during COVID-19 disease and TIM-3 is the most important exhausted marker on CD4
Identifiants
pubmed: 34499819
doi: 10.1002/iid3.526
pmc: PMC8589347
doi:
Substances chimiques
Hepatitis A Virus Cellular Receptor 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1707-1715Subventions
Organisme : Babol University of Medical Sciences
ID : 724132993
Informations de copyright
© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Nat Immunol. 2003 Nov;4(11):1102-10
pubmed: 14556006
FEBS Lett. 2015 Nov 14;589(22):3454-60
pubmed: 26226423
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32098829
J Virol. 2009 Sep;83(18):9122-30
pubmed: 19587053
Immun Inflamm Dis. 2021 Dec;9(4):1707-1715
pubmed: 34499819
Front Cell Infect Microbiol. 2017 Mar 28;7:98
pubmed: 28401068
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8
pubmed: 20679213
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
Immunol Rev. 2019 Nov;292(1):149-163
pubmed: 31883174
Mediators Inflamm. 2019 May 7;2019:4651627
pubmed: 31205451
Curr HIV/AIDS Rep. 2011 Mar;8(1):4-11
pubmed: 21188556
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
F1000Res. 2018 Mar 14;7:316
pubmed: 29560265
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
Microb Pathog. 2019 Mar;128:323-328
pubmed: 30660734
PLoS One. 2018 May 9;13(5):e0197151
pubmed: 29742141
J Immunol. 2012 Jul 15;189(2):755-66
pubmed: 22706088
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
JCI Insight. 2020 May 21;5(10):
pubmed: 32324595
J Immunol. 2012 Aug 15;189(4):1966-74
pubmed: 22802412
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Front Immunol. 2019 Oct 17;10:2465
pubmed: 31681335
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Eur J Immunol. 2012 May;42(5):1080-8
pubmed: 22539281
Annu Rev Immunol. 2010;28:445-89
pubmed: 20192806
PLoS Pathog. 2015 Oct 20;11(10):e1005177
pubmed: 26485519